The Robot Advantage in Rectal Cancer Surgery

In a Chinese randomised trial of 1,171 people with middle or low rectal cancer, robotic surgery was linked to 1.6% locoregional recurrence at three years versus 4.0% after laparoscopy, hazard ratio 0.45 (95% CI 0.22–0.92). This review brings together that result and newer evidence on several surgical techniques, but the strongest apparent advantages remain specific to particular operations and experienced teams.

Research published in Annals of gastroenterological surgery · August 1, 2026

The study at a glance

Published	August 1, 2026
Journal	Annals of gastroenterological surgery
Study design	Structured narrative review of colorectal surgery studies published from January 2024 to July 2026
Who took part	Previously published studies of people undergoing colorectal cancer surgery; the largest randomised rectal surgery trial discussed included 1,171 patients
What was tested	Robotic and laparoscopic surgery, transanal total mesorectal excision, indocyanine green fluorescence imaging, and intracorporeal anastomosis
What was measured	Cancer control, surgical complications, recovery, bowel, urinary and sexual function, and implementation safety

The clearest new evidence concerns rectal cancer

This is a structured narrative review, meaning its authors selected and interpreted recent published studies rather than enrolling patients or producing new results themselves. It covers robotic rectal and colon surgery, difficult pelvic procedures, transanal total mesorectal excision, fluorescence imaging of bowel blood supply, and ways of reconnecting the bowel after colon surgery.

The most consequential trial discussed is REAL, a randomised comparison of robotic and laparoscopic surgery in 1,171 people with nonmetastatic middle or low rectal adenocarcinoma at 11 Chinese centres. Randomisation is valuable because it gives the fairest test of whether the assigned surgical approach caused a difference in outcomes.

At three years, locoregional recurrence, cancer returning in the pelvis or nearby lymph-node area, was 1.6% after robotic surgery and 4.0% after laparoscopic surgery. The hazard ratio was 0.45, with a 95% confidence interval of 0.22 to 0.92. Disease-free survival, the proportion alive without a documented recurrence, was 87.2% versus 83.4%, hazard ratio 0.74 (95% CI 0.56, 0.98). Overall survival was 94.7% after robotic surgery and 93.0% after laparoscopy, a difference that was not statistically significant.

People assigned to robotic surgery also had better urinary, sexual and bowel function at three and six months. Better urinary function and male sexual function continued at 12 months. This is clinically meaningful, because nerve injury during pelvic dissection can affect daily life long after the operation. Still, these outcomes do not establish that every person with rectal cancer will do better with a robot. The trial was conducted by experienced surgeons working within one healthcare system, and its results need confirmation in other settings.

Observational studies from Japan reported more favourable long-term survival after robotic rectal surgery than after laparoscopic or open surgery. Such studies can detect patterns in routine practice, but they cannot prove the operation caused the difference. Patients offered a robot, the hospitals treating them, the surgeon’s experience and the calendar period of treatment may all differ in ways statistical adjustment cannot fully remove.

Difficult operations may be where technology helps most

Robotic instruments may have their greatest practical value in a narrow pelvis, particularly for very low rectal tumours or operations requiring fine dissection around nerves and blood vessels. The review describes prospective Japanese work showing that robotic ultralow anterior resection and intersphincteric resection can be performed safely at high-volume institutions. These were feasibility findings, not proof that robotic surgery is superior to another approach.

For low rectal tumours, reconstruction can matter as much as tumour removal. In a 135-patient subanalysis, stapled reconnection of the bowel was associated with better anorectal function over three years than hand-sewn reconnection, while complications, cancer outcomes, and urinary and sexual function were comparable. The appropriate reconstruction still depends on whether the surgeon can obtain a safe cancer margin and preserve the sphincter.

The review also addresses lateral lymph node dissection, an operation that removes lymph nodes along the pelvic sidewall in selected rectal cancers. It can improve local clearance in carefully chosen circumstances, but it passes close to pelvic nerves, the ureter and major vessels. Robotic access may assist meticulous dissection, yet removal of autonomic nerves can still lead to urinary dysfunction regardless of the platform.

Pelvic exenteration, which may involve removing rectal cancer together with involved pelvic organs, is another setting where a robotic approach may be feasible for selected patients. Feasibility is not a reason to stretch the boundaries of surgery. A complete, safe cancer operation, backed by multidisciplinary planning and a willingness to convert to open surgery where needed, remains the priority.

Transanal surgery shows why training and audit matter

Transanal total mesorectal excision, or TaTME, approaches part of rectal removal from below through the anus. It was developed to improve access to low tumours, where working from the abdomen can be difficult. Its history is a warning that a technically successful operation can still have unacceptable cancer outcomes when a technique spreads faster than training and oversight.

In the TaLaR randomised trial, three-year disease-free survival was 82.1% after TaTME and 79.4% after laparoscopic total mesorectal excision. The absolute difference was 2.7 percentage points, with a 97.5% confidence interval from −3.0 to 8.1 percentage points. This met the trial’s definition of noninferiority, meaning TaTME was not shown to be worse than laparoscopy by more than a prespecified amount. That amount was a 10-percentage-point margin, which is wide enough that the finding deserves restraint.

Implementation data explain the concern. Norway suspended TaTME after local recurrence in 12 of 157 patients, or 7.6%, often involving multiple sites in the pelvis. In a Dutch experience, recurrence affected 10.0% of patients among each centre’s first ten cases. A later audit found recurrence fell from 12.5% during the early learning period to 3.4% with greater experience.

These figures do not mean TaTME is inherently unsafe in every setting. They show that outcomes are closely tied to training, supervised introduction, careful case selection and ongoing review of results. For now, the review supports reserving TaTME for low rectal tumours where it solves a defined access problem, rather than treating it as a routine substitute for other established operations.

Fluorescence and internal bowel joins have narrower benefits

After surgeons remove a section of bowel, they may reconnect the ends with an anastomosis. An anastomotic leak is a serious complication, and poor blood supply is one possible contributor. Indocyanine green, or ICG, is a dye that fluoresces under near-infrared light, allowing a surgical team to assess blood flow in real time before making or completing a bowel join.

Individual randomised trials of ICG have had mixed results. A 2026 meta-analysis combining nine randomised trials and 4,754 patients found lower leak rates overall and after left-sided, rectal and low anterior resections, with relative risks ranging from 0.62 to 0.66. A relative risk below 1 indicates fewer leaks in the ICG group. The pooled analysis found no clear benefit for right-sided colon resections. That supports selective use where the risk and anatomy make perfusion assessment most useful, rather than routine use in every colorectal operation.

For colon surgery, robotic colectomy appears feasible, but it has not clearly outperformed established laparoscopic colectomy for the average patient. The review suggests that robots may be more useful when anatomy is complex, a more extensive lymph-node dissection is planned, or surgeons plan an intracorporeal anastomosis.

An intracorporeal anastomosis is a bowel reconnection made inside the abdomen, rather than bringing bowel outside through an incision to create the join. Studies reviewed found faster return of bowel function, shorter hospital stays and fewer wound-related problems in some comparisons. One trial reported leak rates below 2% with both internal and external reconnection. The long-term cancer equivalence of intracorporeal anastomosis has yet to be established, so its clearest current advantages concern recovery and where the specimen is removed, including a possible reduction in extraction-site hernias.